Andere talen HOOKIPA Pharma Inc.

Aandelen

HOOK

US43906K1007

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,733 ^USD	-4,17%		-6,80%	-9,51%

10/04	HOOKIPA Pharma Inc. kondigt aan dat het Europees Geneesmiddelenbureau Prime Designation heeft toegekend voor het onderzoeksproduct HB-200	CI
22/03	HOOKIPA Pharma Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

HOOKIPA Pharma Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(4)	17/04
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	16/04
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration	10/04
HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200	10/04
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	25/03
HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
HOOKIPA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/03
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	22/03
North American Morning Briefing : Stocks Struggle After New Records	22/03
North American Morning Briefing : Stock Futures -2-	13/03
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference	06/03
HOOKIPA Pharma to Cut 30% of Workforce in Restructuring	29/01
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs	29/01
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs	29/01
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization	17/01
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization	16/01
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization	16/01
HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024	16/01
Top Premarket Gainers	21/12
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences	21/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen HOOKIPA Pharma Inc.

Aandelen

HOOK

US43906K1007

Andere talen

Filters